0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995)

LUClNDA B. BARNARD, M.D.; GRANTHAM WILLIAM G., M.D., Ph.D.; PRESTON LAMBERTON, M.D.; THOMAS M. O'DORISIO, M.D.; and IVOR M. D. JACKSON, M.R.C.P.
[+] Article and Author Information

Grant support: in part by National Institutes of Health Grants AM34540 (Dr. Jackson) and RR-34 (Ohio State University Hospitals).

Presented in part at the annual meeting of the American Society for Clinical Investigation, May 1986, Washington, D.C.

▸Requests for reprints should be addressed to Dr. Ivor M. D. Jackson, Division of Endocrinology, Brown University, Rhode Island Hospital, 593 Eddy Street; Providence, RI 02902.


Providence, Rhode Island; and Columbus, Ohio


© 1986 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1986;105(6):856-861. doi:10.7326/0003-4819-105-6-856
Text Size: A A A

Six patients with resistant acromegaly were given a longacting somatostatin analogue (SMS 201-995) for 5 to 12 months. The clinical response was dramatic; relief of headache occurred within minutes of the injection. The mean 24-hour growth hormone levels fell acutely after the administration of 50 or 100 µg every 12 hours, especially in four patients with small tumors (p < 0.001). Dosages of up to 1500 µg/d were necessary to produce maximum lowering of growth hormone secretion in some patients. On long-term treatment, plasma somatomedin-C levels fell in all patients and became normal in four. Plasma immunoreactive levels of SMS 201-995 related inversely to growth hormone concentration: A reproducible threshold for growth hormone inhibition in five of the patients, ranging from 70 to 1200 pg/mL, was maintained for 6 to 8 hours after the injections. This somatostatin analogue is effective in the treatment of acromegaly, has no major side effects, and causes only transient changes in carbohydrate metabolism.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)